Biocartis inks deal with Bristol-Myers Squibb for IdyllaTM MSI testing
Category: #health  By Paroma Bhattacharya  Date: 2019-03-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biocartis inks deal with Bristol-Myers Squibb for IdyllaTM MSI testing

Biocartis Group, a molecular diagnostics company based in Belgium, has reportedly signed a collaboration deal with the American pharmaceutical company, Bristol-Myers Squibb, for the IdyllaTM MSI testing with immune-oncology therapies and the potential registration as a companion diagnostic.

Sources revealed that MSI (Microsatellite Instability) is an outcome of the body’s DNA MMR (mismatch repair) system getting inactivated. As a result, spontaneous errors occurring during the normal DNA replication process are not rectified further and eventually lead to tumor growth. Sources added that MSI-High status is found in different tumor types, including around 15 percent of CRC (colorectal) tumors. MSI is also considered an independent factor, possibly predicting a patient’s response to specific immunotherapies.

Herman Verrelst, CEO, Biocartis, commented on the latest move, saying that the company’s association with Bristol-Myers Squibb, which is a frontrunner in the field of immune-oncology therapies, is quite an achievement. He believes that MSI testing can be made accessible to a growing number of patients, given the benefits of the company’s IdyllaTM MSI test. He also added that a wider patient population can benefit from immunotherapies, which will make Biocartis turn personalized medicine into an everyday reality.

As per a press release issued by Biocartis, the entirely-automated IdyllaTM MSI test has received the CE-IVD grading on the 28th of February 2019. It gives information regarding the MSI status 6, 7, 8 of CRC tumors from just a piece of FFPE9 tumor tissue in about 150 minutes. The report added that the collaboration agreement includes joint developments as well as the MSI test registrations for uses in several indications, geographies and commercial settings. Moreover, the prime focus will be on the test’s registration in the United States as a companion diagnostic in metastatic colorectal cancer (mCRC).

For the record, Opdivo (nivolumab), along with low-dose Yervoy (ipilimumab), is the first-ever immune-oncology combination treatment of Bristol-Myers Squibb, that is U.S. FDA-approved for MSI-High or dMMR (mismatch repair deficient) mCRC, which has advanced the treatment with specific chemotherapies.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...